These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18594015)

  • 1. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
    Wansley EK; Chakraborty M; Hance KW; Bernstein MB; Boehm AL; Guo Z; Quick D; Franzusoff A; Greiner JW; Schlom J; Hodge JW
    Clin Cancer Res; 2008 Jul; 14(13):4316-25. PubMed ID: 18594015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
    Bernstein MB; Chakraborty M; Wansley EK; Guo Z; Franzusoff A; Mostböck S; Sabzevari H; Schlom J; Hodge JW
    Vaccine; 2008 Jan; 26(4):509-21. PubMed ID: 18155327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
    Bilusic M; Heery CR; Arlen PM; Rauckhorst M; Apelian D; Tsang KY; Tucker JA; Jochems C; Schlom J; Gulley JL; Madan RA
    Cancer Immunol Immunother; 2014 Mar; 63(3):225-34. PubMed ID: 24327292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.
    Boehm AL; Higgins J; Franzusoff A; Schlom J; Hodge JW
    Cancer Immunol Immunother; 2010 Mar; 59(3):397-408. PubMed ID: 19756595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
    Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
    J Natl Cancer Inst; 1992 Jul; 84(14):1084-91. PubMed ID: 1619682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice.
    Xiang R; Silletti S; Lode HN; Dolman CS; Ruehlmann JM; Niethammer AG; Pertl U; Gillies SD; Primus FJ; Reisfeld RA
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):856s-864s. PubMed ID: 11300483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
    Hance KW; Rogers CJ; Zaharoff DA; Canter D; Schlom J; Greiner JW
    Clin Cancer Res; 2009 Apr; 15(7):2387-96. PubMed ID: 19276249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
    Ahn E; Kim H; Han KT; Sin JI
    Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
    Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J
    J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.
    Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
    Clin Cancer Res; 2004 May; 10(10):3273-81. PubMed ID: 15161680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice.
    Li D; Hua S; Fan Y; Xu S; Duan X; Liu L; Che Y; Li S; Tan Y
    Immunol Lett; 2011 Mar; 135(1-2):124-8. PubMed ID: 21073899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
    Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
    Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.